In the BioHarmony Drug Report Database

"Preview" Icon

Ramelteon

Rozerem (ramelteon) is a small molecule pharmaceutical. Ramelteon was first approved as Rozerem on 2005-07-22. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against melatonin receptor type 1A and melatonin receptor type 1B. In addition, it is known to target Rubredoxin. Rozerem’s patent is valid until 2021-11-16 (FDA).

 

Trade Name

 

Rozerem
 

Common Name

 

ramelteon
 

ChEMBL ID

 

CHEMBL1218
 

Indication

 

sleep initiation and maintenance disorders
 

Drug Class

 

Selective melatonin receptor agonist

Image (chem structure or protein)

Ramelteon structure rendering